Bausch Health

BHC

Börsenwert 2,36 Mrd. $

LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. The findings will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, taking place October 9-14, 2026, in Nashville, Tennessee.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir.

LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m.

ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.

BHC, CDNA, DOLE and CHEF offer defensive exposure as consumer confidence falls amid inflation and geopolitical tensions.

BHC, OPHC and TRVG made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 22nd, 2026.

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and Kazakhstan. LAVAL, QC, Sept.

This year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. LAVAL, QC, Aug. 27, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. “Helping people see better to live better starts with tackling the challenges patients still face every day,” said Bausch + Lomb CEO Brent Saunders. “These results suppor.